The Authors: Dr Coxson is an Associate Professor of Radiology specializing in quantitative imaging of the lung. His research interest includes CT and optical coherence tomography and how these techniques relate to lung structure–function relationships in health and disease. Dr Eastwood is a National Health and Medical Research Council (Australia) Senior Research Fellow and Professor at University of Western Australia with research interests in respiratory and sleep physiology. Dr Williamson is a Respiratory Physician with research interests including lower airway optical coherence tomography, airway mechanics and interventional bronchology. Dr Sin is a Professor of Medicine, who holds a Canada Research Chair in COPD and a senior scholarship with the Michael Smith Foundation for Health Research. His research interests are in identifying new biomarkers to improve the health outcomes of patients with chronic airway diseases.
Phenotyping airway disease with optical coherence tomography
Article first published online: 23 DEC 2010
© 2010 The Authors. Respirology © 2010 Asian Pacific Society of Respirology
Volume 16, Issue 1, pages 34–43, January 2011
How to Cite
COXSON, H. O., EASTWOOD, P. R., WILLIAMSON, J. P. and SIN, D. D. (2011), Phenotyping airway disease with optical coherence tomography. Respirology, 16: 34–43. doi: 10.1111/j.1440-1843.2010.01888.x
Conflict of Interest: J.W. and P.E. are listed as inventors on a provisional patent application associated with clinical applications of anatomical optical coherence tomography. H.O.C. has received an honorarium for serving on the steering committee for the ECLIPSE project for GlaxoSmithKline; was the co-investigator on two multi-centre studies sponsored by GlaxoSmithKline and has received travel expenses to attend meetings related to the project; has three contract service agreements with GlaxoSmithKline to quantify the CT scans in subjects with COPD and a service agreement with Spiration Inc. to measure changes in lung volume in subjects with severe emphysema; has received a fee for speaking at a conference and related travel expenses from AstraZeneca. D.D.S. has received research funding from AstraZeneca and GSK and has performed consultancy work for both companies.
All authors made equal contributions to the article.
SERIES EDITOR: DARRYL KNIGHT
- Issue published online: 23 DEC 2010
- Article first published online: 23 DEC 2010
- Accepted manuscript online: 2 NOV 2010 10:43AM EST
- Received 8 July 2010; invited to revise 9 August 2010; revised 14 September 2010; accepted 7 October 2010.
- airway disease;
- optical tomography
Airway diseases are a major concern around the world. However, the pace of new drug and biomarker discovery has lagged behind those of other common disorders such as cardiovascular diseases and diabetes. One major barrier in airway research has been the inability to accurately visualize large or small airway remodelling or dysplastic/neoplastic (either pre or early cancerous) changes using non- or minimally invasive instruments. The advent of optical coherence tomography (OCT) has the potential to revolutionize airway research and management by allowing investigators and clinicians to visualize the airway with resolution approaching histology and without exposing patients to harmful effects of ionizing radiation. Thus, with the aid of OCT, we may be able to accurately determine and quantify the extent of airway remodelling in asthma and chronic obstructive pulmonary disease, detect early pre-cancerous lesions in smokers for chemoprevention, study the upper airway anatomy of patients with obstructive sleep apnea in real time while they are asleep and facilitate optimal selection of stents for those with tracheal obstruction. In this paper, we review the current state of knowledge of OCT and its possible application in airway diseases.